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ABSTRACT
A case of systemic mastocytosis associated with a clonal
haematological non-mast cell lineage disease (SM-
AHNMD), where the associated disease is acute erythroid
leukaemia (erythroid/myeloid type), is reported.
Interestingly, molecular studies showed the KITD816V+
mutation not only in the mast cells, but also in the myeloid
blast population and the leukaemic erythroid cells. As is
the case with most erythroid leukaemias, the patient had
a very aggressive clinical course and died shortly after
diagnosis. It is believed that this is the first reported case
of systemic mastocytosis with erythroid leukaemia where
the KITD816V+ mutation was detected in all three cell types.
Molecular findings provide evidence for derivation of these
seemingly morphologically distinct lesions from the same
clonal precursor cell. From a practice standpoint, this case
illustrates the importance of definitively diagnosing the
associated non-mast cell lineage disease due to its
prognostic implications.
A previously healthy, adult individual, in the sixth
decade of life, who had no significant past medical
or surgical history, presented with fatigue. The
only medication was a daily 61 mg aspirin.
A complete blood count revealed pancytopenia
with rare myeloblasts identified (,1%). Overt
dysplasia or circulating mast cells were not
identified. Bone marrow aspirate smears showed
marked erythroid predominance with increased
immature precursors and dysplastic features char-
acterised by circumferential cytoplasmic vacuolisa-
tion, nuclear contour irregularities and
multilobation (fig 1A,B). Myeloblasts were
increased, some smaller in size, with scant cyto-
plasm and minimal granulation (fig 1A,B). Mast
cells were quite conspicuous and exhibited atypical
spindled morphology (fig 1A,B). Megakaryocytes
were decreased; rare small, dysplastic, hypolobated
forms were seen.
A 500-cell differential count showed 69% ery-
throid precursors, 18% myeloblasts and 13% other
(granulocytic precursors, lymphocytes, eosino-
phils). The bone marrow core biopsy was hyper-
cellular, with abnormally thickened bony
trabeculae and paratrabecular compact aggregates
of spindled cells (fig 1C,D). The remaining marrow
showed expanded groups of blastic mononuclear
cells, many with pronormoblast cytology (round
nuclei with multiple, elongated nucleoli), often
associated with more mature appearing red cell
precursors.
Immunohistochemistry for tryptase highlighted
paratrabecular mast cell aggregates with atypical
spindled morphology and increased interstitial
mast cells (fig 1F). The mast cells showed aberrant
CD25 positivity (data not shown). CD117 showed
two patterns of staining intensity: strong positiv-
ity in the mast cells, and weaker positivity in the
groups of pronormoblasts and scattered myelo-
blasts (fig 1E). CD34 showed increased blasts
(,10–15%), and haemoglobin A showed the
clusters of immature normoblasts. The presence
of increased and spindled mast cells forming
compact dense aggregates with aberrant CD25
expression indicated systemic mastocytosis (SM).
The non-mast cell component was best classified
as acute erythroid leukaemia (erythroid/myeloid
type), based on the World Health Organization
(WHO) 2008 criteria.
Conventional cytogenetics revealed a normal
karyotype. Fluorescence in-situ hybridisation for
BCR-ABL1 was negative. Although material was
available for initial flow cytometry, it was insuffi-
cient for specific cell sorting for further genetic
analysis. KITD816V+ mutational analysis was thus
performed for further support of systemic masto-
cytosis and to investigate a possible clonal relation-
ship of SM and the associated erythroid
leukaemia.1
To specifically address the question of whether
KITD816V is present in neoplastic mast cells, about
100 tryptase+ (mast) cells were individually micro-
dissected and pooled within the tip of a PCR tube,
where the cell material was digested with protei-
nase-K overnight and then amplified by nested
PCR with outer primers KIT-1F (59- CAC AGA
GAC TTG GCA GCC AG -39) and KIT-1B (59-
CAG GAT TTA CAT TAT GAA AGT CAC GG-
39), and inner primers KIT-2F (59- CAG CCA GAA
ATA TCC TCC TTA CT -39) and KIT-2B (59- TTG
CAG GAC TGT CAA GCA GAG -39).1 For
genotyping, an aliquot of the nested PCR product
was analysed by the technique of ‘‘melting point
analysis’’ with a pair of hybridisation probes.2 The
same procedures were performed with cells micro-
dissected from separately immunostained slides, ie,
CD34+ early progenitors/blasts, and glyco-
phorinA+ erythroid blasts. Individually performed
melting point analyses of amplification products
gained from the three immunostained cell types
disclosed strong signals for the activating point
mutation KITD816V in tryptase+ mast cells, CD34+
progenitor cells/blasts, and glycophorin A+ ery-
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throblasts (fig 2A,B). For all mutational analyses, slides from
formalin-fixed, paraffin-embedded bone marrow biopsy speci-
men were used. All experiments were repeated separately with
the same results. The clinical course was very aggressive, and
the patient died shortly after diagnosis.
DISCUSSION
We report the first case of systemic mastocytosis with
associated clonal haematological non-mast-cell lineage disorder
(SM-AHNMD) where the KITD816V+ mutation was simulta-
neously identified in the mast cells, neoplastic erythroid cells
and myeloblasts. Only rare previous studies have studied the
KITD816V+ mutation within the non-mast cell component.
Similar to our case, Ustun et al utilised microdissection
techniques and found the KITD816V+ mutation within the
neoplastic mast cells as well as the myeloid blasts representing
the AHNMD.3 These findings lend strong support to the notion
that although morphologically different lesions are present;
they all originally derive from the same KITD816V+ progenitor
clone.
In approximately 20–30% of patients with SM, AHNMD is
diagnosed.4 Both the SM and the AHNMD should be diagnosed
and classified according to the World Health Organization 2008
criteria.4 Review of the current literature shows that AHNMD
primarily consists of myeloid malignancies—particularly acute
myeloid leukaemia, chronic myelomonocytic leukaemia and
chronic myelogenous leukaemia.5 There are rare reports of
lymphoid neoplasms, including plasma cell dyscrasia,6 chronic
lymphocytic leukaemia7 and B-lymphoblastic leukaemia,8 asso-
ciated with SM. We now add to this list the rare occurrence of
Figure 1 Bone marrow with systemic mastocytosis and associated haematological non-mast cell lineage disease. (A, B) Bone marrow aspirate
showing increased and spindled mast cells, erythroid predominance with dysplasia including cytoplasmic vacuolisation, and increased myeloblasts
(Wright Giemsa; original magnification 6400 and 6600, respectively). (C, D) Bone marrow core biopsy showing characteristic features of systemic
mastocytosis (osteosclerosis, focal, compact aggregates of pale cells (mast cells) around bone, and associated haematological non-mast cell lineage
disease (cluster of left shifted erythroids) (H&E; original magnification6200 and6600, respectively). (E, F) Immunohistochemical staining with CD117
and tryptase, respectively. The CD117 (E) shows both the mast cell population (dark positive) and the myeloblasts and pronormoblasts (light positive).
The tryptase (F) highlights the mast cell aggregates and spindled morphology.
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KITD816V+ acute erythroid leukaemia (erythroid/myeloid type) as
the AHNMD. Overall, the prognosis of patients with systemic
mastocytosis and associated acute leukaemia is quite poor as in
this current case. It is has been commonly found that the
KITD816V+ mutation is resistant to imatinib therapy,9 and the
mast cell component often persists beyond the eradication of
the non-mast cell disease. While allogeneic stem cell transplan-
tation is considered the most effective treatment option, this
may not always be practical.
We report the first case of KITD816V+ erythroid leukaemia
associated with SM. Biologically, our finding of the presence of
the KITD816V+ clone within the mast cells, neoplastic erythroids
and myeloblasts supports the hypothesis of a common
neoplastic progenitor. Such a progenitor has the capacity of
multiphenotypic differentiation and theoretically should be
eliminated in order to eradicate the disease(s). In this case,
identification of the acute erythroid leukaemia component was
critical as it most likely contributed to the aggressive outcome in
this patient. Future studies of KITD816V+ SM-AHNMD for
KITD816V+ AHNMD will hopefully identify additional cases
derived from a single precursor clone with multilineage
differentiation. Such cases will provide insight into the
biological behaviour of KITD816V+ disease and potentially
translate into the availability of successful targeted therapies.
It could be speculated that two major subtypes of SM-AHNMD
exist: (1) ‘‘true’’ SM-AHNMD, exhibiting the activating point
mutation in both the SM and the ‘‘AHNMD’’ compartment of
the disease; and (2) SM-AHNMD, possibly those disorders
associated with lymphoid neoplasms, where there is a mere
coincidence between two unrelated haematological disorders.
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Take-home messages
c Although myeloid neoplasms are the usual component of
systemic mastocytosis with associated haematological non-
mast cell disease, a few lymphoid malignancies have also
been reported.
c The KITD816V+ mutation can be detected in not only the mast
cells but also the associated neoplastic non-mast cell
component (AHNMD).
c The non-mast cell component often has major prognostic
implications.
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